Literature DB >> 15735799

Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism.

Rainer Vormittag1, Thomas Vukovich, Verena Schönauer, Stephan Lehr, Erich Minar, Christine Bialonczyk, Mirko Hirschl, Ingrid Pabinger.   

Abstract

The role of C-reactive protein (CRP) in venous thromboembolism (VTE) is still under discussion because of controversial results in the literature. Conflicting data may have partly been due to bias by exogenous factors altering CRP levels. We investigated CRP concentrations in patients with spontaneous VTE applying a study design that allowed the measurement of basal high sensitivity (hs)-CRP levels. Patients with a history of deep vein thrombosis (DVT, n=117) and pulmonary embolism (PE, n=97) were compared to healthy individuals (n=104). Hs-CRP levels (mg/dl) were significantly higher in patients (n=214, median/interquartile range: 0.171/0.082-0.366) than in controls (0.099/0.053-0.245, p=0.001). The unadjusted odds ratio (OR) for VTE per 1 mg/dl increase of CRP was 2.8 [95% confidence interval (CI): 1.1-6.8, p=0.03]. This association remained significant after adjustment for factor V Leiden, prothrombin G20210A and factor VIII activity above 230% (OR = 2.9, 95% CI [1.1-7.5]), but became remarkably attenuated and lost its statistical significance after adjustment for BMI alone (OR = 1.7 [0.7-4.0]). CRP was also not independently associated with VTE in subgroups of patients (those with DVT without symptomatic PE, those with PE and patients without established risk factor) in multiple regression analysis. In summary, we observed significantly higher basal hs-CRP levels in patients with spontaneous VTE compared to healthy controls. This association was independent of hereditary and laboratory risk factors for VTE, but lost its significance after adjustment for BMI. Increased basal CRP levels do not appear to represent an independent risk factor for VTE.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735799     DOI: 10.1160/TH04-11-0745

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  11 in total

Review 1.  Statins, inflammation and deep vein thrombosis: a systematic review.

Authors:  April L Rodriguez; Brandon M Wojcik; Shirley K Wrobleski; Daniel D Myers; Thomas W Wakefield; Jose A Diaz
Journal:  J Thromb Thrombolysis       Date:  2012-05       Impact factor: 2.300

2.  Increased expressions of integrin subunit β1, β2 and β3 in patients with cancer ------correlation analysis between risk factors of VTE and expression of core proteins.

Authors:  Yanli Song; Lemin Wang; Fan Yang; Guiyuan Li; Qianglin Duan; Zhu Gong
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  Inflammation markers and incident venous thromboembolism: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort.

Authors:  N C Olson; M Cushman; P L Lutsey; L A McClure; S Judd; R P Tracy; A R Folsom; N A Zakai
Journal:  J Thromb Haemost       Date:  2014-10-31       Impact factor: 5.824

Review 4.  Postoperative risk of venous thromboembolism in rheumatic disease patients.

Authors:  Lauren E Wong; Anne R Bass
Journal:  Curr Rheumatol Rep       Date:  2015-02       Impact factor: 4.592

5.  High-sensitivity C-reactive protein is not a risk factor for venous thromboembolism: the Tromso study.

Authors:  Erin M Hald; Sigrid K Brækkan; Ellisiv B Mathiesen; Inger Njølstad; Tom Wilsgaard; Jan Brox; John-Bjarne Hansen
Journal:  Haematologica       Date:  2011-04-20       Impact factor: 9.941

6.  Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study).

Authors:  Remedios Otero; Aurora Solier-López; Verónica Sánchez-López; Julia Oto; Elena Arellano; Samira Marín; Luis Jara-Palomares; Teresa Elías; María Isabel Asencio; Isabel Blasco-Esquivias; María Rodríguez de la Borbolla; José María Sánchez-Díaz; Macarena Real-Domínguez; Emilio García-Cabrera; Francisco Javier Rodríguez-Martorell; Pilar Medina
Journal:  Cancers (Basel)       Date:  2022-06-02       Impact factor: 6.575

Review 7.  Statins as a preventative therapy for venous thromboembolism.

Authors:  Alex Wallace; Hassan Albadawi; Peter Hoang; Andrew Fleck; Sailendra Naidu; Grace Knuttinen; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 8.  Biomolecular markers of cancer-associated thromboembolism.

Authors:  Diana L Hanna; Richard H White; Ted Wun
Journal:  Crit Rev Oncol Hematol       Date:  2013-03-21       Impact factor: 6.312

9.  C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort.

Authors:  Aaron R Folsom; Pamela L Lutsey; Brad C Astor; Mary Cushman
Journal:  Thromb Haemost       Date:  2009-10       Impact factor: 5.249

10.  Correlation between Deep Venous Thrombosis and Inflammation in Patients after Implantation of Permanent Pacemaker.

Authors:  Jianxin Ma; Lian Cui; Wenjin Huo; Guanghui Wang; Xin Quan; Jinping Zhang
Journal:  Iran J Public Health       Date:  2020-01       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.